NASDAQ · Biotechnology

Genfit S.A. (GNFT) Stock

$8.95 +4.07% NASDAQ: GNFT Healthcare

Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases.

Valuation

MetricValue
Price$8.95
Market Cap$445.68M
P/E Ratio261.07
P/B Ratio5.68
P/S Ratio5.82
EPS (TTM)$0.03
52-Week High$10.00
52-Week Low$2.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2.20%
ROA1.00%
ROCE4.30%
Gross Margin99.55%
Operating Margin4.90%
Net Margin2.25%
Debt/Equity0.90
Current Ratio1.23

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$80.0M$20.0M$29.0M$67.0M
Operating Profit$-83.0M$32.0M$-27.0M$-27.0M$3.0M
Net Profit$-101.0M$67.0M$-24.0M$-29.0M$2.0M
EPS$-2.60$1.23$-0.48$-0.58$0.03
Op Margin-10836.2%39.7%-135.1%-93.0%4.9%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$199.0M$282.0M$216.0M$174.0M$151.0M
Total Liabilities$215.0M$163.0M$121.0M$106.0M$82.0M
Cash$171.0M$259.0M$136.0M$78.0M$82.0M
Borrowings$186.0M$74.0M$75.0M$70.0M$62.0M

Latest News

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire · Jul 8, 2026 GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH GlobeNewswire · Jul 2, 2026 GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma GlobeNewswire · Jun 23, 2026 GENFIT: June 15, 2026 Combined Shareholders Meeting Results GlobeNewswire · Jun 15, 2026 GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-96.0M$100.0M$-73.0M$-55.0M$15.0M
Investing Cash Flow$-2.0M$-4.0M$-46.0M$0$-2.0M
Financing Cash Flow$-6.0M$-2.0M$-2.0M$0$-1.0M
Net Cash Flow$-106.0M$88.0M$-123.0M$-58.0M$4.0M
Free Cash Flow$-97.0M$99.0M$-73.0M$-58.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.96
EV / EBITDA44.38
FCF Yield3.65%
Quick Ratio1.23
Interest Coverage0.69
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
EPRX $6.05 +4.13% -5.99 $202.55M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
IVVD $0.55 +3.10% -3.53 $162.51M 0.00%
MDWD $14.35 -1.85% -7.94 $184.34M 0.00%

About Genfit S.A.

Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company's pipeline further encompasses GNS561, which is in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation as a potential therapy for acute-on-chronic liver failure. Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, it collaborates with Genoscience Pharma to jointly develop and market the investigational treatment GNS561 for CCA. Founded in 1999, Genfit S.A. is headquartered in Loos, France.

Genfit S.A. is headquartered in FR.

Genfit S.A. (GNFT) stock trades at $8.95 with a market capitalization of $445.68M. The stock is valued at a price-to-earnings (P/E) ratio of 261.07, price-to-book of 5.68, price-to-sales of 5.82. Over the past 52 weeks the stock has ranged between $2.55 and $10.00, and currently trades 10.5% below its 52-week high.

On profitability, Genfit S.A. generates a return on equity (ROE) of 2.20%, return on capital employed of 4.30%, an operating margin of 4.90%, a net profit margin of 2.25%.

Official website: www.genfit.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides